Hospital
Commonspirit Oregon
Commonspirit Oregon was paid $29.19M by Medicaid between Jan 2018 and Nov 2024, across 194 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.
33Billing provider infoCOMMONSPIRIT OREGON
ROSEBURG, OR 97471
ROSEBURG, OR 97471
33aNPI1477590198assigned 06/01/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$29.19M
24GClaims784,468
24DCodes billed194
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 127,200 | $4.66M | |
| 2019 | 131,323 | $4.97M | |
| 2020 | 105,724 | $1.91M | |
| 2021 | 102,964 | $4.14M | |
| 2022 | 117,246 | $4.54M | |
| 2023 | 114,752 | $4.75M | |
| 2024incomplete | 85,259 | $4.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 37,035 | 33,510 | $7.65M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 50,846 | 47,161 | $7.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 11,473 | 10,183 | $5.26M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.6% | 19,076 | 17,207 | $1.93M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 12,240 | 11,562 | $1.16M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.9% | 11,782 | 7,828 | $857K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.0% | 1,170 | 1,108 | $579K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 20,997 | 6,616 | $498K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 9,602 | 8,853 | $428K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 1,186 | 1,107 | $386K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 9,206 | 8,219 | $296K |
| 80053 | Comprehensive metabolic panel | <1% | 102,910 | 92,768 | $260K |
182 more codes
| 36415 | Collection of venous blood by venipuncture | <1% | 145,829 | $229K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,868 | $197K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,913 | $192K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 105,240 | $187K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 813 | $185K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,157 | $160K |
| 80061 | Lipid panel | <1% | 18,666 | $126K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,782 | $103K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 485 | $88K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,162 | $73K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,729 | $69K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,172 | $49K |
| 97597 | <1% | 1,013 | $48K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,734 | $45K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,073 | $44K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,073 | $44K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,856 | $36K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,553 | $26K |
| 73630 | <1% | 616 | $26K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 318 | $25K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 39 | $22K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 842 | $19K |
| 88142 | <1% | 1,349 | $19K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,398 | $19K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 442 | $18K |
| 80069 | <1% | 6,843 | $18K | |
| 73610 | <1% | 269 | $14K | |
| 87510 | <1% | 1,064 | $13K | |
| 87480 | <1% | 1,064 | $13K | |
| 87660 | <1% | 1,064 | $13K | |
| 80306 | <1% | 1,388 | $13K | |
| 87070 | <1% | 2,242 | $12K | |
| 80081 | <1% | 183 | $12K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 133 | $11K |
| 59025 | Fetal non-stress test | <1% | 127 | $11K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 56 | $10K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 500 | $10K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 20 | $9K |
| 80074 | <1% | 290 | $8K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 17 | $8K |
| 84439 | <1% | 1,381 | $7K | |
| 86803 | <1% | 899 | $7K | |
| 87081 | <1% | 1,620 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,399 | $6K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 324 | $6K |
| 87902 | <1% | 34 | $6K | |
| 86480 | <1% | 138 | $6K | |
| 87077 | <1% | 1,295 | $6K | |
| 87186 | <1% | 1,161 | $6K | |
| 82728 | <1% | 807 | $5K | |
| 73560 | <1% | 152 | $5K | |
| 83970 | <1% | 379 | $5K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 99 | $4K |
| 86900 | <1% | 69 | $4K | |
| 85018 | <1% | 5,501 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 168 | $4K |
| 97161 | <1% | 83 | $4K | |
| 83550 | <1% | 819 | $4K | |
| 87507 | <1% | 14 | $4K | |
| 80055 | <1% | 105 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,681 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 939 | $3K |
| 29581 | <1% | 45 | $3K | |
| 93017 | <1% | 146 | $3K | |
| 84481 | <1% | 306 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,510 | $3K |
| 87653 | <1% | 107 | $3K | |
| 84100 | <1% | 1,835 | $3K | |
| 83540 | <1% | 820 | $3K | |
| 82248 | <1% | 1,500 | $2K | |
| 87536 | <1% | 50 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 945 | $2K |
| 82570 | <1% | 915 | $2K | |
| 87205 | <1% | 809 | $2K | |
| 85027 | <1% | 964 | $2K | |
| 87340 | <1% | 370 | $2K | |
| 87481 | <1% | 156 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $2K |
| 73562 | <1% | 178 | $2K | |
| 86592 | <1% | 577 | $1K | |
| 84156 | <1% | 948 | $1K | |
| G0378 | Hospital observation service, per hour | <1% | 903 | $1K |
| 99406 | <1% | 109 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,245 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 26 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $1K |
| 85610 | <1% | 607 | $1K | |
| 82607 | <1% | 142 | $1K | |
| 84702 | <1% | 122 | $980.46 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 41 | $938.58 |
| 70486 | <1% | 14 | $937.51 | |
| 86696 | <1% | 90 | $936.43 | |
| 81001 | <1% | 14,100 | $930.38 | |
| 87150 | <1% | 38 | $912.47 | |
| 83735 | <1% | 1,443 | $884.23 | |
| 74022 | <1% | 16 | $692.27 | |
| 82746 | <1% | 96 | $686.99 | |
| 86695 | <1% | 90 | $637.92 | |
| 85651 | <1% | 363 | $589.54 | |
| 83690 | <1% | 8,647 | $496.49 | |
| 83516 | <1% | 19 | $493.95 | |
| 86694 | <1% | 57 | $489.99 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 447 | $417.60 |
| 84132 | <1% | 303 | $410.07 | |
| 87807 | <1% | 46 | $394.63 | |
| 81015 | <1% | 258 | $383.55 | |
| 82950 | <1% | 95 | $333.28 | |
| 82043 | <1% | 121 | $323.32 | |
| 93922 | <1% | 13 | $322.68 | |
| 85014 | <1% | 318 | $315.08 | |
| 29125 | <1% | 13 | $208.00 | |
| 84295 | <1% | 149 | $196.83 | |
| 84484 | <1% | 5,923 | $194.85 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 68 | $187.96 |
| 94664 | <1% | 42 | $173.26 | |
| 97116 | <1% | 28 | $165.69 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 32 | $162.00 |
| 82947 | <1% | 80 | $159.87 | |
| 82565 | <1% | 125 | $159.71 | |
| Q3014 | Telehealth originating site facility fee | <1% | 33 | $153.60 |
| 93296 | <1% | 29 | $139.76 | |
| 93242 | <1% | 12 | $109.40 | |
| 82247 | <1% | 59 | $101.34 | |
| 82784 | <1% | 16 | $93.72 | |
| 85007 | <1% | 38 | $87.78 | |
| 82374 | <1% | 55 | $71.59 | |
| 84550 | <1% | 41 | $69.16 | |
| 81003 | <1% | 309 | $65.08 | |
| 85379 | <1% | 41 | $56.28 | |
| 84436 | <1% | 15 | $38.15 | |
| 80076 | <1% | 30 | $28.11 | |
| 81050 | <1% | 13 | $26.22 | |
| 82150 | <1% | 16 | $25.70 | |
| 88720 | <1% | 2,835 | $24.04 | |
| 81025 | <1% | 1,235 | $23.99 | |
| 86762 | <1% | 66 | $20.14 | |
| 83721 | <1% | 16 | $17.00 | |
| 87430 | <1% | 393 | $13.34 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,584 | $12.32 |
| 86901 | <1% | 69 | $2.09 | |
| 88342 | 0% | 737 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 8,691 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 6,091 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 548 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,621 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 531 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 42 | $0.00 |
| 36416 | 0% | 145 | $0.00 | |
| 83605 | 0% | 38 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 427 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 122 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 26 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 246 | $0.00 |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | 0% | 63 | $0.00 |
| 81000 | 0% | 25 | $0.00 | |
| 86850 | 0% | 69 | $0.00 | |
| 84703 | 0% | 25 | $0.00 | |
| 96376 | 0% | 52 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 17 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 16 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 14 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 29 | $0.00 |
| 83880 | 0% | 30 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 21 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 16 | $0.00 |
| C1769 | Guide wire | 0% | 17 | $0.00 |
| 94760 | 0% | 36 | $0.00 | |
| 87071 | 0% | 18 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,599 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 7,009 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 6,236 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 76 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 43 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 310 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 44 | $0.00 |
| 0296T | 0% | 14 | $0.00 | |
| 73130 | 0% | 12 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 30 | $0.00 |
| 87075 | 0% | 24 | $0.00 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 0% | 12 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 18 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPOINDEXTER, JAMIE (MARKET VP OPERATIONAL FINANCE)
Parent organizationCOMMONSPIRIT HEALTH
| Provider | Location | Paid |
|---|---|---|
| Commonspirit Oregon | Pendleton, OR | $13.70M |
| Commonspirit Oregon | Pendleton, OR | $277K |
| Commonspirit Oregon | Roseburg, OR | $128K |
| Commonspirit Oregon | Roseburg, OR | $92K |
| Commonspirit Oregon | Pendleton, OR | $72K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.